Home » Bear Case Scenario » Bear Case Scenario Gilead Sciences $GILD, $RHHVF, $AMGN, $NONOF

Bear Case Scenario Gilead Sciences $GILD, $RHHVF, $AMGN, $NONOF

Gilead Sciences (Nasdaq:GILD) is about to release earnings. Follow this Bear Case Scenario as you ponder management comments.

Litigation with Roche, Merck, and Idenix will shave Gilead’s Sovaldi profits.

Gilead’s HIV franchise generates 75% of the firm’s revenue. Mission critical dependence on tenofovir,  puts pressure on Gilead’s hepatitis C portfolio to support growth. Exclusivity  expires in 2018. Not that long away in the drug world.

Hep C regimens from Bristol and AbbVie will spark price wars when PBMs learn to negotiate aggressively.

Atripla becomes a formidable generic competitor to Gilead’s newer HIV products by 2021.

George Gutowski writes from a caveat emptor perspective.

Advertisements